KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesBeginning Cash BalanceCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Cash from Operations: 2018-2025

Historic Cash from Operations for Esperion Therapeutics (ESPR) over the last 8 years, with Sep 2025 value amounting to -$4.3 million.

  • Esperion Therapeutics' Cash from Operations rose 87.87% to -$4.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$93.3 million, marking a year-over-year decrease of 262.17%. This contributed to the annual value of -$23.7 million for FY2024, which is 82.54% up from last year.
  • According to the latest figures from Q3 2025, Esperion Therapeutics' Cash from Operations is -$4.3 million, which was up 86.36% from -$31.4 million recorded in Q2 2025.
  • Esperion Therapeutics' Cash from Operations' 5-year high stood at $53.8 million during Q1 2024, with a 5-year trough of -$89.1 million in Q1 2021.
  • In the last 3 years, Esperion Therapeutics' Cash from Operations had a median value of -$24.8 million in 2023 and averaged -$19.8 million.
  • In the last 5 years, Esperion Therapeutics' Cash from Operations surged by 199.03% in 2024 and then crashed by 336.11% in 2025.
  • Quarterly analysis of 5 years shows Esperion Therapeutics' Cash from Operations stood at -$57.7 million in 2021, then grew by 26.40% to -$42.5 million in 2022, then grew by 12.75% to -$37.1 million in 2023, then rose by 5.68% to -$35.0 million in 2024, then surged by 87.87% to -$4.3 million in 2025.
  • Its Cash from Operations was -$4.3 million in Q3 2025, compared to -$31.4 million in Q2 2025 and -$22.6 million in Q1 2025.